Showing results (111-120 of 139) with videos related to
Sort By:
Pageof 14
Science (New York, N.Y.)|December 15, 2022
Synthetic cytokine circuits that drive T cells into immune-excluded tumorsGreg M Allen, Nicholas W Frankel, Nishith R Reddy, et al.Biorxiv : the Preprint Server for Biology|March 22, 2022
A conserved immune trajectory of recovery in hospitalized COVID-19 patientsCassandra E Burnett, Trine Line Hauge Okholm, Iliana Tenvooren, et al.Immunity|July 2, 2022
Mass cytometry reveals a conserved immune trajectory of recovery in hospitalized COVID-19 patientsCassandra E Burnett, Trine Line Hauge Okholm, Iliana Tenvooren, et al.Clinical Colorectal Cancer|March 13, 2026
Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal CancerAndrea Bocobo, Julia Whitman, Bridget P Keenan, et al.Cell|June 5, 2020
Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder CancerDavid Y Oh, Serena S Kwek, Siddharth S Raju, et al.Biorxiv : the Preprint Server for Biology|December 16, 2024
Coordinated variation in the immune systems and microbiomes of healthy humans is linked to tonic interferon statesJoel Babdor, Ravi K Patel, Brittany Davidson, et al.Nature Medicine|January 17, 2017
Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological statesDavid Furman, Junlei Chang, Lydia Lartigue, et al.Journal for Immunotherapy of Cancer|January 17, 2024
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanomaMagdalena Kovacsovics-Bankowski, Johanna M Sweere, Connor P Healy, et al.Philosophical Transactions. Series A, Mathematical, Physical, and Engineering Sciences|February 21, 2018
The ASACUSA antihydrogen and hydrogen program: results and prospectsC Malbrunot, C Amsler, S Arguedas Cuendis, et al.JCI Insight|July 29, 2021
The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetesShen Dong, Kamir J Hiam-Galvez, Cody T Mowery, et al.Pageof 14